Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Hideki GotoSatoshi ItoMasahiro KizakiMasaki YamaguchiNoriko FukuharaKoji KatoToko SaitoYasuhito TeruiSumiko OkuboTomomi SoshinJiewei ZengHideyuki HondaMohamed BadawiJeremy A RossKoji Izutsu

Published in: International journal of clinical oncology (2023)

Ibrutinib plus venetoclax exhibited high response rates and a well-tolerated safety profile in Japanese patients with R/R MCL.

Keyphrases

chronic lymphocytic leukemia
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
open label
hodgkin lymphoma
randomized controlled trial